FcεRIα-based CARs mediated T cell responses to U266 myeloma cells expressing very low levels of mIgE (Figures 3, 7), suggesting that even low mIgE-expressing plasma cells may be targeted in vivo. Here, FCER1A is linked to plasma cell myeloma.